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Abstract 
Background: Murine cell lines are working horses applied as model systems in mul-
tiple research studies in many laboratories. Nonetheless, most of them are not well 
characterized at the genetic level. This diagnosis holds also true for the MMT 
060562 murine breast cancer cell line, also referred to as MMT060562 or MMT-
060562. The aim of the study: To provide detailed cytogenetic characterization of 
the MMT 060562 cancer cell line. Materials and methods: The cell line was stud-
ied by molecular cytogenetics, namely by fluorescence in situ hybridization applying 
all murine while chromosome paints in one probe set and all chromosome-specific 
murine multicolor banding probe sets. Results: For this we present here the first de-
tailed karyotype of the established in 1962 cell line, a comprehensive map of chro-
mosomal imbalances and an in-silico translation of the results to the human genome. 
Surprisingly, MMT 060562 has only few chromosomal aberrations, even a cell clone 
without any gross chromosomal abnormalities in ~40% of the cells, and with most 
aberrant of four cell clones showing a dicentric dic(2;17)(A1A1), a derivative 
del(3)(A3C), a trisomy 6, and a derivative 
der(14)t(13;14)(14pter14D1::14B14D1::13A313qter). Conclusion: It could 
be shown, that MMT 060562 is most similar to human breast cancer of basal-like 
tumor type. Thus, this cell line can serve as a model for a very early breast cancer 
stage and thus closes a gap in the yet available cell lines.   
Keywords: breast cancer (BC); MMT 060562 murine cell line; murine multicolor 
banding (mcb) 
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Introduction. In female breast cancer 
(BC), being a major leading cause of human 
cancer death, survival chance varies still tre-
mendously, depending on many factors like 
awareness, preventive programs, diagnostic 
regimens, and possibilities to treat this disease 
[1]. The incidence of this malignancy is fur-
thermore influenced by such factors as average 
life expectancy in the country the person is de-
rived from, life style, individual estrogen-
levels, number of children of the woman, and 
family history of cancer, including adverse 
gene mutations [1, 2]. As BC is heterogenic, it 
is divided into subtypes according to morphol-
ogy, molecular profiles, and specific biomarker 
expression [3]. Accordingly, various subtypes 
may have different prognoses, clinical out-
comes, and maybe in need of specific treat-
ment regimens [3, 4]. Biomarkers studied to 
perform BC subclassifications may include 
oncogene and tumor suppressor gene expres-
sion levels, as well as that of other gene-
products, like estrogen-, progesterone-, human 
epidermal growth factor-2- (HER-2/ ERBB2) 
and epidermal growth factor-receptor, or cy-
tokeratin 5 or nuclear protein Ki67 [5, 6]. 
Thus, BC may be classified in (a) luminal A-
like, (b) luminal B-like (HER2-positive and 
HER2-negative), (c) HER2-overexpressing, 
and (d) triple-negative subtypes [3, 6]. Fur-
thermore, liquid biopsy plays an increasingly 
important role in BC follow-up [7]. 
Various treatment regimens for BC sub-
types are available [6, 8], however, severe side 
effects cannot be excluded in many of these ap-
proaches. Also, aggressive courses of disease 
and limitations in BC treatment are not unusual 
[9]. Therefore, research on BC-biology, as well 
as for new treatment strategies is imperative 
[10], which are undertaken in cell cultures 
based on murine BC cell lines [5].  
The MMT 060562 murine BC-cell line, 
also referred to as MMT060562 or MMT-
060562, has been applied in about 2 dozen 
studies (see [11]), and, as most of other such 
cell lines [12], still been not characterized in 
detail genetically. According to ATCC, this 
cell line was established in 1962 [13] as being 
derived from a hybrid female C57BL/6xAf 
mouse as a spontaneous malignant neoplasm 
of the mouse mammary gland [14]. To the 
best of our knowledge the karyotype of this 
cell line was never published before, howev-
er, according to ATCC, MMT 060562 has a 
modal number of 40 chromosomes with a 
range of 36 to 81, and a stem line number be-
ing diploid [13], while ECAAC gives a de-
scription that the cell line is diploid with 2n = 
40 [14]. To close the gap in the literature, here 
we present the first molecular cytogenetic 
characterization of the MMT 060562 cell line.  
Material and Methods 
Cell line. The MMT 060562 cell line 
was purchased from the American Type Cul-
ture Collection (ATCCR CCL-51™; Wesel 
Germany) and grown adherently according to 
the company’s instructions: the cells were cy-
togenetically worked up as previously de-
scribed [12].  
Molecular cytogenetics. FISH was done 
as previously reported [15] applying whole 
chromosome paints (“SkyPaintTM DNA Kit 
M-10 for Mouse Chromosomes”, Applied 
Spectral Imaging, Edingen-Neckarhausen, 
Germany) for multicolor-FISH (mFISH), and 
murine chromosome-specific multicolor 
banding (mcb) probe mixes for FISH-banding 
[16]. At least 30 metaphases were analyzed 
for each probe set (Zeiss Axioplan microsco-
py, equipped with ISIS software (MetaSys-
tems, Altlussheim, Germany).  
Data analyses. Imbalances and break-
points of MMT 060562 were determined ac-
cording to mcb data and aligned to human 
homologous regions using the Ensembl and 
the UCSC Genome Browser, as previously 
described [12]. The obtained data were com-
pared to genetic changes known from human 
BCs as previously done [5]. 
Ethics Statement. According to the Eth-
ical Committee (medical faculty) and the An-
imal Experimentation Commission of the 
Friedrich Schiller University, there are no eth-
ical agreements necessary for studies involv-
ing murine tumor cell lines like MMT 
060562. 
Results. MMT 060562 is a cell line 
with nearly stable diploid karyotype, only few 
single cell aberrations were present, which are 
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could be divided in two clones, with clone 2 
having three sub-clones.  
 Clone 1 can be considered as the an-
cestor and has a completely normal murine 
karyotype representing 42% of the studied 
metaphases; karyotype: 40,XY.  
 Clone 2, falling in three subclones, 
has as typical aberration in common an addi-
tional chromosome 6: 
 clone 2a showed a trisomy of chro-
mosome 6 and an inversion in a chromosome 
2 (11.3% of the cells); karyotype: 
41,XY,inv(2)(C3E5),+6; 
 clone 2b1 (28.5% of the cells) ac-
quired a complicated aberration involving 
chromosomes 13 and 14; 
41,XY,+6,der(14)t(13;14)(14pter14D1::14
B14D1::13A313qter); 
 clone 2b2 (18.2% of the cells) ac-
quired an additional aberration involving 




13qter) (Fig. 1). 
FISH-data translated to CGH-data is 
summarized in Table 1 and Fig. 2A. An in-
silico translation of those results to the human 
genome identified the corresponding homolo-




Fig. 1. Murine multicolor banding (mcb) was applied on chromosomes of the MMT 060562 cell 
line – here the result for clone 2b2 is shown. This figure depicts the summary of 20 chromosome-
specific FISH-experiments as typical pseudocolor banding. Derivative chromosomes consisting of 
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Beginning of Table 1 
 
Homologous regions of the MMT 060562 mouse cell line CNVs, translated to human 
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End of Table 1 
 
Homologous regions of the MMT 060562 mouse cell line CNVs, translated to human 
 























































































2A1 n.a. breakpoint 
2C3 2q23 breakpoint 
2E5 15q15 breakpoint 
3A3 3q26.2 breakpoint 
3C 4q31.1 breakpoint 
14D1 13q14.1 breakpoint 
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Fig. 2. Copy number variations detected in the MMT 060562 cell line are summarized here with 
respect to a diploid-basic karyotype. Gains are shown as green bars and losses are red, and breaks 
are registered as arrows. (A) Imbalances found in the cell line depicted along a murine chromosome 
set; (B) Results translated and projected along the human chromosome set. 
 
 
Comparison with literature. The corre-
sponding homologous regions of the MMT 
060562 cell line compared with the common 
imbalances in related to human BC [5, 17, 18] 
revealed copy number variations in 9 of 21 
regions (43%) known to harbor oncogenes 
and tumor suppressor genes (Table 2). The 
here reported breakpoints of MMT 060562 
compared to chromosomal breaks of human 
BC presented a congruency of 6%, only (Ta-
ble 3). The genetic alterations in the cell line 
correlated with the molecular subtype for hu-
man BC as shown in Table 4. The results re-
vealed the best correspondence between 
MMT 060562 and human BC subtype basal-
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Oncogenes and tumor suppresser genes of importance in BC according  
to the literature [17, 18] and their involvement in gains or loss of copy numbers  
in the studied cell line 
 
Oncogenes and tumor suppressor 
genes 
Gene loci in human MMT 060562 
NRAS 1p22 or p13 no CNV 
MSH2 2p22 gain 
RAF1 3p25 gain 
RARβ2  3p24 no CNV 
MLH1  3p21 no CNV 
APC  5q21 gain 
MYB 6q22-q23 no CNV 
IGFII-R 6q26 gain 
MYC 8q24 no CNV 
CDKN2A (p16INK4) 9p21 no CNV 
PTEN  10q23 no CNV 
HRAS 11p15.5 no CNV 
CCND1 11q13 no CNV 
INT2 11q13 no CNV 
ATM  11q22 no CNV 
CDKN1B (p27kip1) 12p13 gain 
KRAS2 12p12.1 gain 
BRCA2 13q12 gain 
RB1  13q14.2 gain 
CDH1 (E-cadherin) 16q22 no CNV 
TP53 (p53) 17p13 no CNV 
ERBB2 17q21 no CNV 
BRCA1 17q21 no CNV 
SERPINB5 (maspin) 18q21 no CNV 
STK11 (LKB1) 19p13 gain 
   
SUM of concordance in CNVs of potentially affected regions 9/21 
 







Azawi S, et al. First molecular cytogenetic characterization … 11 
 
Table 3 
Breakpoints in MMT 060562 compared to the observed acquired breaks  
in human BCs according to the literature [5]. Concordances with human breakpoints 
are highlighted in bold 
 
Breakpoint acc. to human genome Human BC MMT 060562 
1p33 + - 
1q25.3 + - 
2p23 - + 
2q31.3 + - 
3p26.1 + (+) 
3p12.3 + - 
3q21.3 + - 
4q22.3 + - 
4q26 + - 
4q31.23 + (+) 
5p14.2 + - 
5q13.2 + - 
5q14.3 + - 
6q12 + - 
8q23.3 + - 
8q24.22 + - 
9p24.2 + - 
9p21 + - 
10p11.21 + - 
11p15.5 + - 
12q12.1 + - 
12q24.31 + - 
13q21.2 + - 
13q14.1 - + 
14q32 + - 
15q15 - + 
16q13.3 + - 
17p12 + - 
17q21 + - 
19p13.1 + - 
20q13.3 + - 
22q12.2 + - 
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Copy number changes associated with molecular subtypes of human BC, according to [19], 
with the copy number variants (CNVs) in the MMT 060562 cell line.  
Concordances with human CNVs (in italics) are highlighted in bold 
DNA changes in BC Subtypes Human BC MMT 060562 
HER2+ 
  
17q11.1~12 gain no CNV 
17q21.31~23.2 gain no CNV 
SUM of concordance 0/2 
Basal-like tumors 
  
4p15.31 loss no CNV 
5q12.3~13.2 loss gain 
5q33.1 loss no CNV 
6p12.3 gain gain 
6p21.1~23 gain gain 
8q24.21~24.22 gain no CNV 
10p12.33~14 gain no CNV 
10q23.33 loss no CNV 
12q13.13~13.3 loss no CNV 
15q15.1 loss gain 
15q21.1 loss gain 
SUM of concordance 2/11 
Luminal A 
  
1q21.3~44 gain no CNV 
16p13.12~13.13 gain no CNV 
16q11.2~13 loss no CNV 
16q22.1-24.1 loss no CNV 
SUM of concordance  0/4 
Luminal B 
  
1p31.3 loss gain 
8p21.2~23.1 loss no CNV 
17q23.2 gain no CNV 
SUM of concordance 0/3 
Note: no CNV – no copy number variant 
 
Discussion. Heterogeneity of BC is one 
of the reasons that its biology is overall still 
poorly understood. Correspondingly, basic 
research and studies testing new potential 
therapeutics are necessary [9; 20]. MMT 
060562 is a murine BC cell line yet not char-
acterized cytogenomically in detail. Thus, its 
reluctant use in research studies, according to 
PUBMED [11] only ~20 papers are published 
using this cell line, here we did the first de-
tailed molecular cytogenetic study to close 
this gap. The same approach as previously 
undertaken for several other murine cell lines 
was done for MMT 060562 [5, 12, 15, 16,  
21-23].  
The MMT 060562 cell line presents a 
normal karyotype in ~40% of the studied 
cells, which is surprising for an almost 60-
year-old cell line. Most likely it would be an 
ideal candidate to be studied by sequencing, 
to find submicroscopic mutations leading 
cells on the path towards BC-malignization. 
Also it is striking that since its establishment 
MMT 060562 cells did not tertaploidize, as 
reported mainly for human cell lines [24] and 
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16, 21-23]. To the best of our knowledge, the 
MMT 060562 cell line is the less chromoso-
mal aberrant malignant cell line ever reported. 
However, it is definitely a cell line, which in-
duced tumors in nude mice [25].  
Conclusion. Overall and in conclusion, 
the MMT 060562 cell line is a very interest-
ing model system for early human BC, which 
should be studied in more detail and applied 
in corresponding studies for new therapeutica. 
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